All In Biotech

Investigational drug · Phase 3

177Lu-edotreotide PRRT

Also called: 177Lu-DOTATOC, 177Lu-Edo, Peptide Receptor Radionuclide Therapy, 177Lu-DOTATOC 177Lu-Edo

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neuroendocrine Tumors.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

15

Any phase or sponsor naming "177Lu-edotreotide PRRT"

First trial start

2017

Feb 2, 2017

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "177Lu-edotreotide PRRT", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neuroendocrine Tumors

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "177Lu-edotreotide PRRT" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2,165 on PubMed

Also in development for Neuroendocrine Tumors

  • Lutetium[177Lu] Oxodotreotidedotatate, 177Lu-DOTA0-Tyr3-OctreotatePhase 33 trials

    Sinotau Pharmaceutical Group · Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma

  • tirapazaminePhase 32 trials

    Zhejiang Raygene Pharmaceuticals Co., Ltd · HCC, Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic

  • CVM-1118TRX-818Phase 22 trials

    TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors

  • CRN09682Phase 21 trial

    Crinetics Pharmaceuticals Inc. · SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm

  • CTX-471Phase 21 trial

    Compass Therapeutics · Neuroendocrine Neoplasm, Neuroendocrine Carcinomas, Neuroendocrine Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.